

Anxiety and Depression in Adult First Seizure Presentations

Ciaran Lane, Candice Crocker, Karen Legg, Mallory Borden,
Bernd Pohlmann-Eden

ABSTRACT: *Objective:* To define the prevalence of psychiatric symptoms of anxiety and depression in patients at the time of their first seizure presentation to a neurologist. *Methods:* Our pilot study uses a cohort approach with multimodal data (clinical, social, structural [3T magnetic resonance imaging], and functional [electroencephalogram]). We screened 105 patients referred to the Halifax First Seizure Clinic between 2014 and 2016 and 51 controls. All participants completed two screening questionnaires: Neurological Disorders Depression Inventory for Epilepsy and Generalized Anxiety Disorder 7-Item. After applying the exclusion criteria, the study population consisted of 57 patients with unprovoked first seizure and 31 controls. The prevalence of anxiety and depression was based on cutoff scores of >15 and >14 respectively. *Results:* Unprovoked first seizure patients showed higher prevalence of depression (33%) compared with control (6%) with an odds ratio (OR) of 2.75 (95% confidence interval [CI], 0.72-10.5). There was no significant difference in the prevalence of anxiety between control subjects (9.7%) and unprovoked first seizure patients (23%). Subcategory analysis conducted after diagnosis confirmation revealed significantly increased OR of depression in patients diagnosed with new-onset epilepsy (OR, 11.6; 95% CI, 2.1-64.0) and newly diagnosed epilepsy (OR, 20.0; 95% CI, 2.2-181), but not first seizure only patients (OR, 2.2; 95% CI, 0.28-17.6) compared with control. *Conclusions:* Our study supports a bidirectional relationship between the first seizure and depression. Prevalence rate of depression increased with duration of undiagnosed epilepsy at the time of first clinical assessment.

RÉSUMÉ: *Anxiété et dépression chez des patients adultes victimes d'une première crise convulsive.* *Objectifs:* Définir la prévalence des symptômes d'anxiété et de dépression chez des patients adultes victimes d'une première crise convulsive ayant consulté un neurologue. *Méthodes:* Notre étude pilote a fait appel à une approche par cohortes qui utilise des données multimodales à la fois cliniques et sociales mais aussi structurelles (IRM 3 Tesla) et fonctionnelles (EEG). Au total, 105 patients aiguillés vers la *Halifax First Seizure Clinic* entre 2014 et 2016, de même que 51 sujets témoins, ont fait l'objet d'un dépistage. À cet effet, tous les participants à l'étude ont complété deux questionnaires : le *Neurological Disorders Depression Inventory* pour l'épilepsie et le *GAD-7 (Generalized Anxiety Disorder 7-Item)*. Une fois appliqués nos critères d'exclusion, notre échantillon était composé de 57 patients victimes d'une première crise convulsive non provoquée et de 31 sujets témoins. La prévalence de l'anxiété et de la dépression a été évaluée en fonction de valeurs seuils supérieures à 15 et à 14 respectivement. *Résultats:* Les patients victimes d'une première crise convulsive non provoquée ont montré une prévalence plus élevée de dépression (33 %) si on les compare aux sujets témoins (6 %), le rapport de cotes (RC) étant de 2,75 (intervalle de confiance 95 % [IC], 0,72-10,5). Aucune différence notable n'a été relevée en ce qui a trait à la prévalence d'anxiété chez les sujets témoins (9,7 %) et les patients victimes d'une première crise convulsive non provoquée (23 %). Une analyse plus approfondie, menée après la confirmation d'un diagnostic et en établissant une comparaison avec les sujets témoins, a toutefois révélé un accroissement notable de symptômes dépressifs dans le cas de patients chez qui l'on avait diagnostiqué la réapparition d'une crise épileptique (RC 11,6; IC 95 %, 2,1-64,0) et chez qui l'on avait posé un premier diagnostic d'épilepsie (RC 20,0; IC 95 %, 2,2-181) mais pas chez les patients seulement victimes d'une première crise convulsive (RC 2,2; IC 95 %, 0,28-17,6). *Conclusions:* Notre étude soutient donc qu'il existe un lien bidirectionnel entre la dépression et l'apparition d'une première crise convulsive. De plus, les taux de prévalence de la dépression ont tendance à augmenter plus l'on retarde l'établissement d'un diagnostic d'épilepsie à la suite d'une première évaluation clinique.

Key words: comorbidities, anxiety, depression, seizure, screening

doi:10.1017/cjn.2017.285

Can J Neurol Sci. 2018; 45: 144-149

Key Point Box

- Depression is increased in unprovoked first seizure patients at first presentation compared with control population.
- The prevalence of depression increased with a longer duration of undiagnosed epilepsy at the time of first clinical assessment.

Seizures can be considered a result of a complex process in the brain resulting from an imbalance of metabolic and biological variables. Population studies show that 25% to 30% of first

seizures are acutely provoked by disturbances in brain chemistry caused by direct insult to the brain or metabolic disturbances.^{1,2} Seizures that do not result directly from acute systemic, metabolic, or toxic cerebral insult are considered unprovoked.³

From the Epilepsy Program (CL, CC, KL, MB, BP-E), Division of Neurology, Queen Elizabeth II Health Science Center, Dalhousie University, Halifax, NS, Canada; Brain Repair Center (CL, CC, BP-E), Dalhousie University, Halifax, NS, Canada.

RECEIVED MAY 14, 2017. FINAL REVISIONS SUBMITTED SEPTEMBER 27, 2017. DATE OF ACCEPTANCE OCTOBER 25, 2017.

Correspondence to: Bernd Pohlmann-Eden, Brain Repair Centre, Dalhousie University, Life Sciences Research Institute, 1348 Summer St., North Tower, Halifax, NS, B3H 4R2 Canada Email: B.Pohlmann-Eden@dal.ca

For unprovoked seizures, the individually contributing risk factors for ictogenesis are still poorly understood and difficult to disentangle, particularly when structural and functional abnormalities and hereditary background are missing. More recently, psychiatric conditions such as depression and anxiety have been discussed as either potential risk factors or indicators for subsequent seizure occurrence.⁴ In people with epilepsy through all stages of the disease, there are high comorbidity rates of depression and anxiety, with a wide range reported at between 20% and 80%.⁵ Interpretation is still challenging because multidimensional factors are likely playing a role in psychiatric manifestation in epilepsy such as: seizure etiology, location electroencephalogram (EEG) focus, duration of epilepsy, medication side effects, socioeconomic sequels, and stigmatization.² Others have suggested that these comorbid conditions in seizures are best explained by an imbalance in the neurochemical milieu and/or common or shared mechanism using similar neuroanatomical structures.⁶ The exact nature of the relationship between epilepsy and psychiatric mood disorders is still not well understood.⁷

The objective of our study was to define the prevalence of psychiatric symptoms of anxiety and depression in patients at the time of their first clinical presentation for seizure diagnosis.

METHODS

Study Population

All patients referred to the Halifax First Seizure Clinic (HFSC) at the Queen Elizabeth II Health Sciences Centre between 2014 and 2016 were eligible for the study. A total of 57 patients and 31 controls were recruited to participate. Inclusion criteria were any participants referred to the HFSC for examination of possible first episode of seizure and older than 18 years. Exclusion criteria included all subjects with a lower than grade 7 education, known significant cognitive dysfunction or psychomotor delay, progressive neurological

disease, provoked seizure, psychogenic nonepileptic seizure, evidence for already established seizure or epilepsy diagnosis in their medical history, or presence of prior psychiatric comorbidity. Control participants were recruited from nonblood relatives or partners of patients who were present at the appointment (Figure 1). The Research Ethics Board at the Nova Scotia Health Authority approved this study.

Measures of Anxiety and Depression

At the time of the referred patients' initial visit to the HFSC, all potential participants were immediately informed of the nature of study before even having seen the specialist (MD, epileptologist) or the epilepsy nurse practitioner (NP). With this algorithm, we avoided the potential bias of the anxiety of an extensive assessment and counselling and potentially a diagnosis of epilepsy by the MD or NP on a patient's test performance. Patients were asked to provide consent to participate, and afterwards completed the following tests under supervision of the research assistant:

1. Neurological Disorders Depression Inventory for Epilepsy (NDDI-E): This self-report screening tool uses six-item scale for identification of major depression in epilepsy. Scores >15 are considered positive for major depressive episode, with specificity of 90% and sensitivity of 81% with a positive predictive value of 0.62.⁸
2. Generalized Anxiety Disorder 7-Item (GAD-7) scale: This is a self-report seven-item anxiety scale instrument for identification of generalized anxiety disorder. Scores >14 are considered positive for severe anxiety. This tool has a specificity of 92% and sensitivity 56% with a positive likelihood ratio of 7.2.⁹

Subsequently, all patients were then seen by an MD and NP for full comprehensive assessment, neurology examination, diagnosis, counselling, and defining further diagnostic steps and treatment decisions. Despite being referred to the HFSC for a first seizure, following the comprehensive assessment, some participants were found to have a history of undiagnosed seizures before




Figure 1: Flow chart of study population recruitment and categorization.

the index seizure that resulted in their referral. Those found to have a history of seizures for less than 12 months were defined to have new-onset epilepsy (NOE) and those with seizures dating back beyond 12 months were categorized as newly diagnosed epilepsy (NDE).¹⁰ Magnetic resonance imaging and routine and sleep-deprived EEG were completed as part of the comprehensive diagnostic workup. Magnetic resonance imaging findings in this study are reported with regard to their topographical distribution. Patient and diagnostic variables were obtained following the appointment through medical chart review (age, gender, level of education).

Statistical Analysis

Statistical analysis was performed using SPSS statistical software, version 23 (IBM Corp.). Participants with scores of ≥ 15 for NDDI-E and ≥ 14 for GAD-7 were dichotomized as presence or absence of depression and anxiety. Chi-square odds ratios (ORs) were calculated for control versus unprovoked seizure patient for both anxiety and depression. All statistical tests were significant at the 95% confidence interval (CI).

RESULTS

Demographic Comparisons

Our study included 57 unprovoked first seizure subjects and 31 age-matched healthy controls. Level of education did not significantly differ between control participants compared with seizure patients. There were more males in the patient population, but this distribution difference did not rise to the level of statistical significance (Table 1).

Results of Screening Instruments

In our healthy control population, 6.5% screened positive for depression (NDDI-E >15), whereas 33% of our unprovoked first seizure participants screened positive ($p=0.01$). Performance on the GAD-7 did not differ significantly between groups; 9.7% of controls had severe anxiety compared with 23% of unprovoked first seizure patients ($p=0.14$, Figure 2). The Pearson-Chi test among unprovoked first seizure patients was significant for depression ($p=0.005$), but not for anxiety ($p=0.43$, Figure 2).

Subcategorization of the unprovoked first seizure participants was then conducted as first seizure (unprovoked single seizure, $n=15$), NOE (seizures occur within 12 months, $n=24$), and NDE (seizures occur longer than 12 months, $n=18$; Figure 1)¹⁰ Further Pearson-Chi testing showed first seizure had 13.3% screen positive for depression with an OR of 2.23 compared with control; this did not reach statistical significance (OR, 2.2; 95% CI, 0.28-17.6).

Table 1: Sociodemographic information for study population

		Control (n = 31)	Unprovoked seizure(s) (n = 57)	p value
Age	Mean	41.2 (14.5)	39.9 (17.2)	0.72
Gender	% Male	48.4% (15)	52.6% (30)	0.70
Education	< High school	16.1% (5)	15.4% (16)	0.28
	High school	22.6% (7)	30.4% (17)	
	Postsecondary	61.3% (19)	25.6% (24)	




Figure 2: Forest plot comparing the presence of anxiety and depression in unprovoked first seizure patients versus control population.

Positive screening for depression in participants with NOE was 37.5% of the sample (OR, 11.6; 95% CI, 2.1-64) and an even greater number of those with NDE were seen at 44.4% (OR, 20; 95% CI, 2.2-181).

The vast majority of patients presented with generalized tonic-clonic seizures when presenting to HFSC ($n=52$). Seizures were further classified into focal if there was evidence for clinical focal onset, dyscognitive seizures, preceding auras, or EEG findings suggestive of focal findings. All others were classified as generalized seizures. Unprovoked first seizure patients were dichotomized as either presence or absence of anxiety or depression as described by the screening questionnaire cutoffs. The results are summarized in Tables 2 and 3. Unprovoked first seizure patients with comorbid depression were found to have no differences in focal onset, frequency, EEG findings, number of medications, alcohol, tobacco, or marijuana use compared with those without psychiatric comorbidities. Similarly, unprovoked first seizure patients with comorbid anxiety were found to have no difference in focal onset, frequency, EEG findings, number of medications, alcohol, tobacco, or marijuana use compared with those without psychiatric comorbidities. Magnetic resonance imaging results were normal in two-thirds of all patients (Tables 2 and 3); pathological findings were overall subtle and ranged from remote discrete vascular lesions to nonspecific scars or showed global diffuse changes. No gross lesions such as tumors or large infarcts were identified. Temporal abnormalities were significantly more present in both the patients with comorbid anxiety (38.5%) and the patients with comorbid depression (26.5%) compared with patients with no psychiatric comorbidities (0.0%), which showed no abnormalities in this region (Tables 2 and 3).

DISCUSSION

First seizure presentations represent a significant challenge for practitioners to individually evaluate the risk of a seizure recurrence and provide optimal counseling. This patient group provides an unique opportunity to learn more about subtle mechanisms of disease evolution by analyzing group patterns.³ Our study is an innovative approach that focuses on psychiatric comorbidities as potential risk factors or indicators for seizure recurrence among well-established, known prognostic factors such as etiology and abnormal EEG. Although previous studies have attempted to retrospectively analyze this population for prevalence of anxiety and

Table 2: Comparison of demographic and diagnostic information for unprovoked seizure patients with and without depression

		No depression (n = 38)	Depression (n = 19)	p value
Gender	% Male	44.7% (17)	68.4% (13)	0.99
Age		39.66 (17.24)	40.32 (17.59)	0.13
Highest level of education*	< High school	15.8% (6)	47.4% (9)	0.01
	High school	34.2% (13)	21.1% (4)	0.25
	Postsecondary	50.0% (19)	31.6% (6)	0.19
Seizure classification	Focal	52.6% (20)	63.2% (12)	0.45
	General	44.7% (17)	36.8% (7)	0.57
	Unclassified	2.6% (1)	0.0% (0)	0.53
Seizure frequency	Once	36.8% (14)	10.5% (2)	0.05
	<1 month	39.5% (15)	47.4% (9)	0.57
	>1 month	15.8% (6)	15.8% (3)	1.00
	>1 week	7.9% (3)	26.3% (5)	0.07
EEG	Normal	68.4% (26)	52.6% (10)	0.24
	Abnormal	28.9% (11)	42.1% (8)	0.32
Brain imaging*	Normal	68.4% (26)	63.2% (12)	0.69
	Frontal lobe abnormality	7.9% (3)	0.0% (0)	0.39
	Global abnormality	15.8% (6)	10.5% (2)	0.59
	Occipital lobe abnormality	2.6% (1)	0.0% (0)	0.79
	Parietal lobe abnormality	2.6% (1)	0.0% (0)	0.79
	Temporal lobe abnormality	0.0% (0)	26.3% (5)	0.02
	Thalamus abnormality	2.6% (1)	0.0% (0)	0.79
Number of medications		1.33 (1.93)	1.42 (1.95)	0.16
Alcohol	% yes	71.1% (27)	73.7% (14)	0.83
Smoking	% yes	36.8% (14)	36.8% (7)	1.00
Marijuana	% yes	26.3% (10)	31.6% (6)	0.19

Bold text indicates significant difference with Fisher's Exact Test.

*Indicates significant difference with Chi-Square Test.

depression, our study evaluated patients for these items at their first presentation to help understand a potential underlying directional relationship.^{4,5} Here, we used screening questionnaires as a tool in clinical practice to quantify subjective variables.⁹ In particular, the NDDI-E and GAD-7 are two validated self-reported screening questionnaires with high sensitivity and specificity for depression and anxiety, respectively.^{8,11-13} We attempted to control the effect of hospital environment on anxiety and depression by recruiting our control population from the nonblood relative or partner of patients at the time of visit. Our study protocol also required that all patients were screened for psychiatric comorbidities before they entered the doctor's office and received any potentially concerning medical information.

In our unprovoked first seizure patients, screening with the NDDI-E indicated depression had a prevalence of 33.0% similar to other reports on patient populations with epilepsy and a comorbid diagnosis of depression, but this rate is higher than the reported prevalence based on survey studies and studies on implantable cardioverter-defibrillator population databases.^{5,14,15} Retrospective studies on prevalence of previous depression before first seizure onset report lower prevalence of 12.0% and 3.9%.^{4,5} One explanation for this discrepancy is possible coding errors and incomplete

data collection through retrospective chart review compared with personal screening. Alternatively, the GAD-7 and NDDI-E have a false-positive rate of 10% and 8%, respectively, which may account for some variation in our study population. In terms of control participants, we found a prevalence of control population that indicated prevalence of depression of 6%, similar to the Canadian Community Health survey that reported a yearly prevalence rate of major depressive episode of 4.8% in the adult general population.¹⁶

Anxiety screening was positive for 23% of unprovoked first seizure patients and 9.7% of control participants, which was not significantly different between the groups. In comparison, Brandt et al found that in a population of long-term refractory focal epilepsy, 19.2% of the patients had an anxiety disorder, whereas the 2012 Canadian Community Health Survey quotes a yearly general population prevalence rate of 4.8%.^{16,17} It is also possible that the hospital environment or the associated uncertainty around the appointment outcome resulted in increased anxiety for both groups. Additionally, there may be a bias toward less anxious patients in the patient sample; it could that the most anxious patients did not attend their appointments, as is known to occur in treatment-resistant epilepsy.¹⁸

Subcategorizing patients with the diagnosis of first seizure, NOE, or NDE based on first clinical history has been reported to

Table 3: Comparison of demographic and diagnostic information for unprovoked seizure patients with anxiety and without anxiety

		No anxiety (n = 44)	Anxiety (n = 13)	p value
Gender	% Male	54.5% (24)	46.2% (6)	0.59
Age		38.75 (17.39)	43.69 (16.64)	0.51
Highest level of education*	< High school	18.2% (8)	53.8% (7)	0.01
	High school	36.4% (16)	7.7% (1)	0.07
	Postsecondary	45.5% (20)	38.5% (5)	0.65
Seizure classification	Focal	52.3% (23)	69.2% (9)	0.28
	General	47.7% (21)	23.1% (3)	0.12
	Unclassified	0.0% (0)	7.7% (1)	0.15
Seizure frequency	Once	29.5% (13)	23.1% (3)	0.65
	<1 month	43.2% (19)	38.5% (5)	0.76
	>1 month	13.6% (6)	23.1% (3)	0.42
EEG	>1 week	13.6% (6)	15.4% (2)	0.87
	Abnormal	31.8% (14)	38.5% (5)	0.66
	Normal	65.9% (29)	53.8% (7)	0.43
Brain imaging*	Normal	72.7% (32)	46.2% (6)	0.08
	Frontal lobe	6.8% (3)	0.0% (0)	0.59
	Global	15.9% (7)	7.7% (1)	0.46
	Occipital lobe	2.3% (1)	0.0% (0)	0.97
	Parietal lobe	0.0% (0)	7.7% (1)	0.15
	Temporal lobe	0.0% (0)	38.5% (5)	0.008
Number of medications	Thalamus	2.3% (1)	0.0% (0)	0.96
		1.10 (1.86)	2.23 (1.92)	0.06
Alcohol	% Yes	75.0% (33)	61.5% (8)	0.34
Smoking	% Yes	31.8% (14)	53.8% (7)	0.15
Marijuana	% Yes	27.3% (12)	30.8% (4)	0.80

help determine patient prognosis.² We found that the prevalence rate of depression increases with duration of undiagnosed epilepsy at the time of first clinical assessment. That is, the diagnoses of first seizure, NOE, and NDE represent a sequentially increased risk of presenting with depressive symptoms (Figure 3). Based on our results, we speculate that an increase in duration of seizure history leads to an increase in depression through upset of the neuroanatomical structures important in mood stabilization. This idea of a underlying neurobiological mechanism to seizure development through psychiatric disorders has been proposed previously by Kanner,^{6,19,20} and others have reported an increase in seizure frequency was associated with increased prevalence of depressive symptoms.²¹ One suggested mechanism may be that depression increases seizure frequency through the mechanism of sleep deprivation.²² Taken together, we add further clinical evidence of a bidirectional relationship between depression and seizures based on length of seizure occurrence.²³ Anxiety, however, did not show the same intercorrelation in our study populations.

Interestingly, both unprovoked first seizure patients with comorbid anxiety or depression had a significant greater number of abnormalities in imaging of the temporal lobe region. This finding has to be interpreted with all caution because the numbers




Figure 3: Odds ratio of anxiety and depression for first seizure, new onset epilepsy, and newly diagnosed epilepsy.

of these subgroups are very small. It provides further support to the current view that in few patients a common pathway in the highly connected temporal lobe may explain the cooccurrence of seizure onset and psychiatric comorbidity.

Our study is limited by its use of screening questionnaires as a tool for the diagnosis of anxiety and depression because they are not a substitute for a full psychiatric examination. Further, we are aware that our control group is not an ideal population and results may be biased by the fact that nonblood relatives such as partners may be exposed to similar anxiety levels because they share a common household and social environment. Furthermore, our study is significantly underpowered to draw clear conclusions regarding semiology of first seizure presentations.

In conclusion, evidence from our study supports a bidirectional relationship between the onset of seizures and the presence of psychiatric symptoms of depression at time of initial presentation. Certain patient and diagnostic variables may act as red flags for further psychiatric investigation and careful reassessment for risk of seizure recurrence. We conclude that screening for psychiatric disorders at the first presentation of unprovoked seizure provides valuable information that may help determine the course of a patient's illness. Appropriate management of these disorders must be an integral component of caring for patients with epilepsy.

ACKNOWLEDGMENTS AND FUNDING

This research was supported by a research grant from the Epilepsy Association of Nova Scotia.

DISCLOSURES

BP-E received a grant from the Epilepsy Association of Nova Scotia. MB received a grant from the Epilepsy Association of Nova Scotia. CC, KL, and CL have nothing to disclose.

REFERENCES

1. Annegers JF, Hauser WA, Lee JR, Rocca WA. Incidence of acute symptomatic seizures in Rochester, Minnesota, 1935-1984. *Epilepsia*. 1995;36:327-33.
2. Pohlmann-Eden B, Beghi E, Camfield C, Camfield P. The first seizure and its management in adults and children. *BMJ*. 2006;332:339-42.
3. Pohlmann-Eden B. Conceptual relevance of new-onset epilepsy. *Epilepsia*. 2011;52:1-6.
4. Hesdorffer DC, Hauser WA, Olafsson E, Ludvigsson P, Kjartansson O. Depression and suicide attempt as risk factors for incident unprovoked seizures. *Ann Neurol*. 2005;59:35-41.
5. Tellez-Zenteno JF, Patten SB, Jetté N, Williams J, Wiebe S. Psychiatric comorbidity in epilepsy: a population-based analysis. *Epilepsia*. 2007;48:2336-44.
6. Kanner AM. Depression in epilepsy: a neurobiologic perspective. *Epilepsy Curr*. 2005;5:21-7.
7. Adelow C, Andersson T, Ahlborn A, Tomson T. Hospitalization for psychiatric disorders before and after onset of unprovoked seizures/epilepsy. *Neurology*. 2012;78:396-401.
8. Micoulaud-Franchi J-A, Lagarde S, Barkate G, et al. Rapid detection of generalized anxiety disorder and major depression in epilepsy: validation of the GAD-7 as a complementary tool to the NDDI-E in a French sample. *Epilepsy Behav*. 2016;57:211-16.
9. Spitzer RL, Kroenke K, Williams JBW, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. *Arch Intern Med*. 2006;166(10):1092-7; doi: 10.1001/archinte.166.10.1092.
10. Pohlmann-Eden B, Legg K, Crocker CE. Definition of new-onset epilepsy versus newly diagnosed epilepsy: role of time domain. *Epilepsia*. 2012;53:1277.
11. Gilliam FG, Albertson B. Identifying epilepsy surgery candidates in the outpatient clinic. *Epilepsy Behav*. 2011;20:156-59; doi: 10.1016/j.yebeh.2010.12.022.
12. Friedman DE, Kung DH, Laowattana S, Kass JS, Hrachovy RA, Levin HS. Identifying depression in epilepsy in a busy clinical setting is enhanced with systematic screening. *Seizure*. 2009;18:429-33.
13. Cole AJ. New screening tool for identifying major depression in patients with epilepsy. *Nat Clin Pract Neurol*. 2006;2:656-57.
14. Wiegartz P, Seidenberg M, Woodard A, Gidal B, Hermann B. Co-morbid psychiatric disorder in chronic epilepsy: recognition and etiology of depression. *Neurology*. 1999;53:S3-8.
15. Fiest KM, Dykeman J, Patten SB, et al. Depression in epilepsy: a systematic review and meta-analysis. *Neurology*. 2013;80:590-99.
16. Meng X, D'Arcy C. Common and unique risk factors and comorbidity for 12-month mood and anxiety disorders among Canadians. *Can J Psychiatry*. 2012;57:479-87.
17. Brandt C, Schoendienst M, Trentowska M, et al. Prevalence of anxiety disorders in patients with refractory focal epilepsy—a prospective clinic based survey. *Epilepsy Behav*. 2010;17:259-63.
18. Hamilton KT, Anderson CT, Dahodwala N, et al. Utilization of care among drug resistant epilepsy patients with symptoms of anxiety and depression. *Seizure*. 2014;23:196-200.
19. Kanner AM. Can neurobiological pathogenic mechanisms of depression facilitate the development of seizure disorders? *Lancet Neurol*. 2012;11:1093-102.
20. Kanner AM. Is depression associated with an increased risk of treatment-resistant epilepsy? Research strategies to investigate this question. *Epilepsy Behav*. 2014;38:3-7.
21. Thapar A, Roland M, Harold G. Do depression symptoms predict seizure frequency—or vice versa? *J Psychosom Res*. 2005;59:269-74.
22. Jackson MJ, Turkington D. Depression and anxiety in epilepsy. *J Neurol Neurosurg Psychiatr*. 2005;76:i45-47.
23. Kanner AM, Schachter SC, Barry JJ, et al. Depression and epilepsy: epidemiologic and neurobiologic perspectives that may explain their high comorbid occurrence. *Epilepsy Behav*. 2012;24:156-68.